When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD

Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) have been traditionally linked to one another. Recent studies suggest that NAFLD may be increasingly common in other types of diabetes such as type 1 diabetes (T1DM) and less frequently ketone-prone and Maturity-onset Diabetes of the Young (MODY) diabetes. In this review, we address the relationship between hyperglycemia and insulin resistance and the onset and progression of NAFLD. In addition, despite the high rate of patients with T2DM and other diabetes phenotypes that can alter liver metabolism and consequently develop steatosis, fibrosis, and cirrhosis, NALFD screening is not still implemented in the daily care routine. Incorporating a clinical algorithm created around a simple, non-invasive, cost-effective model would identify high-risk patients. The principle behind managing these patients is to improve insulin resistance and hyperglycemia states with lifestyle changes, weight loss, and new drug therapies.

• Publication year

  2022

• Venue

  Journal of Clinical Medicine

• Publication date

  2022-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/jcm11123286PMID 35743358PMCID 9225139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.

  2022cited by this paper
• Metabolic-associated fatty liver disease and lipoprotein metabolism

  2021cited by this paper
• Ethnic differences in beta cell function occur independently of insulin sensitivity and pancreatic fat in black and white men

  2021cited by this paper
• Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes

  2021cited by this paper
• Vaccination in Chronic Liver Disease: An Update

  2021cited by this paper
• Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.

  2021cited by this paper
• IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.

  2021cited by this paper
• Nonalcoholic fatty liver disease: another leap forward

  2021cited by this paper
• Natural history of NASH

  2021cited by this paper
• Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes.

  2021cited by this paper
• Shear Wave Elastography Reveals a High Prevalence of NAFLD-related Fibrosis even in Type 1 Diabetes

  2021cited by this paper
• Causal variants in Maturity Onset Diabetes of the Young (MODY) – A systematic review

  2021cited by this paper
• Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis

  2021cited by this paper
• Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update.

  2021cited by this paper
• Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

  2021cited by this paper
• Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

  2021cited by this paper
• Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes

  2021cited by this paper
• Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study

  2020cited by this paper
• The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform

  2020cited by this paper
• Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease.

  2020cited by this paper
• Mortality in Biopsy-Confirmed Nonalcoholic Fatty Liver Disease

  2020cited by this paper
• Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study

  2020cited by this paper
• Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.

  2020cited by this paper
• 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021.

  2020cited by this paper
• Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: A systematic review and meta-analysis.

  2020cited by this paper
• Approach to the Patient with MODY-Monogenic Diabetes.

  2020cited by this paper
• ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue

  2020cited by this paper
• Microvascular complications of type 2 diabetes mellitus.

  2020cited by this paper
• Mechanisms of Fibrosis Development in NASH.

  2020cited by this paper
• Time in Range, as a Novel Metric of Glycemic Control, Is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes

  2020cited by this paper
• Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and Their Parents

  2020cited by this paper
• Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2020cited by this paper
• Bariatric surgery during the evolution of fatty liver–A randomized clinical trial comparing gastric bypass and sleeve gastrectomy based on transient elastography

  2020cited by this paper
• Mechanisms of impaired pancreatic β-cell function in high-fat diet-induced obese mice: The role of endoplasmic reticulum stress

  2020cited by this paper
• Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study

  2020cited by this paper
• Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes

  2020cited by this paper
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

  2020cited by this paper
• Maturity-onset diabetes of the young type 5 a MULTISYSTEMIC disease: a CASE report of a novel mutation in the HNF1B gene and literature review

  2020cited by this paper
• Microvascular Complications of Type 2 Diabetes Mellitus

  2020cited by this paper
• FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).

  2020cited by this paper
• Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

  2020cited by this paper
• NAFLD and cardiovascular diseases: a clinical review

  2020cited by this paper
• Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.

  2019cited by this paper
• Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology

  2019cited by this paper
• 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020

  2019cited by this paper
• Sex and racial/ethnic differences in the prevalence of overweight and obesity among U.S. college students, 2011–2015

  2019cited by this paper
• Hyperglycemia induces key genetic and phenotypic changes in human liver epithelial HepG2 cells which parallel the Leprdb/J mouse model of non-alcoholic fatty liver disease (NAFLD)

  2019cited by this paper
• Effect of alcohol consumption on nonalcoholic fatty liver disease.

  2019cited by this paper
• Unraveling the Regulation of Hepatic Gluconeogenesis

  2019cited by this paper
• Association between Pancreatic Atrophy and Loss of Insulin Secretory Capacity in Patients with Type 2 Diabetes Mellitus

  2019cited by this paper
• Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide

  2019cited by this paper
• 17q12 Deletion Syndrome as a Rare Cause for Diabetes Mellitus Type MODY5

  2018cited by this paper
• Prevalence of Obesity and Severe Obesity in US Children, 1999–2016

  2018cited by this paper
• Racial/Ethnic Disparities in Diabetes Quality of Care: the Role of Healthcare Access and Socioeconomic Status

  2018cited by this paper
• Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

  2018cited by this paper
• Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.

  2018cited by this paper
• Non‐severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial

  2018cited by this paper
• Socio‐economic status and HbA1c in type 2 diabetes: A systematic review and meta‐analysis

  2018cited by this paper
• Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

  2018cited by this paper
• Mechanisms of NAFLD development and therapeutic strategies

  2018cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018cited by this paper
• Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.

  2018cited by this paper
• Dermatologic manifestations of endocrine disorders.

  2017cited by this paper
• Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis

  2017cited by this paper
• Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study

  2017cited by this paper
• Influence of hyperglycemia on liver inflammatory conditions in the early phase of non‐alcoholic fatty liver disease in mice

  2017cited by this paper
• Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012

  2017cited by this paper
• Updated 24‐year trend of Type 1 diabetes incidence in children in Poland reveals a sinusoidal pattern and sustained increase

  2017cited by this paper
• Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients

  2017cited by this paper
• Sweet Sixteenth for ChREBP: Established Roles and Future Goals.

  2017cited by this paper
• The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study.

  2017cited by this paper
• Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments

  2017cited by this paper
• Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial

  2017cited by this paper
• Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.

  2017cited by this paper
• NAFLD and diabetes mellitus

  2017cited by this paper
• Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications.

  2017cited by this paper
• Effects of Metreleptin in Pediatric Patients With Lipodystrophy

  2017cited by this paper
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

  2016cited by this paper
• The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline

  2016cited by this paper
• Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A–MODY cohort

  2016cited by this paper
• Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis

  2016cited by this paper
• Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.

  2016cited by this paper
• Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline.

  2016cited by this paper
• EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?

  2016cited by this paper
• Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor ‐γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations

  2016cited by this paper
• Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.

  2016cited by this paper
• Environmental risk factors for type 1 diabetes.

  2016cited by this paper
• Regulation of glucose metabolism from a liver-centric perspective

  2016cited by this paper
• Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice

  2016cited by this paper
• Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage

  2016cited by this paper
• Insulin Clearance Is Associated with Hepatic Lipase Activity and Lipid and Adiposity Traits in Mexican Americans

  2016cited by this paper
• Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes

  2016cited by this paper
• Prevalence of overweight, obesity and metabolic syndrome components in children, adolescents and young adults with type 1 diabetes mellitus

  2015cited by this paper
• Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment

  2015cited by this paper
• Maturity-onset diabetes of the young (MODY): an update

  2015cited by this paper
• Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD

  2015cited by this paper
• Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

  2015cited by this paper
• Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls

  2015cited by this paper

• Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review

  2025cites this paper
• Syringic acid attenuates sodium arsenite-induced hepatotoxicity and diabetes in mice via suppression of oxidative stress/inflammation/apoptosis pathways

  2025cites this paper
• The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction

  2025cites this paper
• Evidence of phenolic compounds as modulators of ChREBP and NRF2 in type 2 diabetes: a review of their potential for drug development

  2025cites this paper
• Oligonucleotide therapies for nonalcoholic steatohepatitis

  2024cites this paper
• Association of Hepatic Steatosis and Fibrosis Indices With Insulin Sensitivity and Inflammation in the POP-ABC Study

  2024cites this paper
• Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

  2024cites this paper
• Research Progress on Correlation between Body Composition Changes and Disease Pro-gression of Type 2 Diabetes

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping

  2024cites this paper
• Reconstruction of the Hepatic Microenvironment and Pathological Changes Underlying Type II Diabetes through Single-Cell RNA Sequencing

  2024cites this paper
• An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease

  2024cites this paper
• Alleviation of Hepatic Steatosis by Alpha-Defensin Is Associated with Enhanced Lipolysis

  2023cites this paper
• Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level

  2023influential citation
• Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table.

  2023cites this paper
• Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology

  2022cites this paper